Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Gets FDA Emergency Use OK for Test to Measure Level of SARS-CoV-2 Antibodies

12/01/2020 | 11:58am EST

By Colin Kellaher

Roche Holding AG on Tuesday said the U.S. Food and Drug Administration granted emergency-use authorization for its Elecsys anti-SARS-CoV-2 S antibody test.

The Swiss pharmaceutical company said the semi-quantitative blood test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus.

Roche said the test specifically detects antibodies against the SARS-CoV-2 spike protein, which is the target of many Covid-19 vaccines in development.

Roche said it will begin shipping the Elecsys test in the next week, adding that Laboratory Corp. of America will be the first lab to offer the testing option in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-20 1158ET

Stocks mentioned in the article
ChangeLast1st jan.
LABORATORY CORPORATION OF AMERICA HOLDINGS 0.91% 225.74 Delayed Quote.10.90%
ROCHE HOLDING AG 0.22% 318.9 Delayed Quote.2.98%
All news about ROCHE HOLDING AG
06:00aROCHE : DZ Bank Lifts Price Target on Roche, Maintains Hold Recommendation
MT
05:59aROCHE HOLDINGS AG : Credit Suisse sticks Neutral
MD
05:51aROCHE : Liberum Lifts Price Target on Roche, Maintains Hold Recommendation
MT
02:26aROCHE HOLDINGS AG : Jefferies maintains a Buy rating
MD
01/19CHUGAI PHARMACEUTICAL : Supports the Japan Climate Initiative's Calling to Raise..
AQ
01/18ROCHE ANNUAL GENERAL MEETING 2021 : Exercising of shareholder rights via the ind..
AQ
01/18PRESS RELEASE : Roche Annual General Meeting 2021: Exercising of shareholder rig..
DJ
01/15ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating
MD
01/14Qiagen warns against using standard tests to track coronavirus variants
RE
01/13CHUGAI PHARMACEUTICAL : Conducts Digital Transformation in Manufacturing with IB..
AQ
More news
Financials
Sales 2020 59 737 M 67 065 M 67 065 M
Net income 2020 14 387 M 16 152 M 16 152 M
Net cash 2020 3 176 M 3 565 M 3 565 M
P/E ratio 2020 19,5x
Yield 2020 2,92%
Capitalization 273 B 307 B 307 B
EV / Sales 2020 4,52x
EV / Sales 2021 4,25x
Nbr of Employees 97 735
Free-Float 83,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 363,84 CHF
Last Close Price 318,20 CHF
Spread / Highest target 37,0%
Spread / Average Target 14,3%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG2.98%307 190
JOHNSON & JOHNSON3.43%428 525
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160
ABBVIE INC.4.69%198 051